Cagrilintide is an, long-acting synthetic amylin analogue developed by Novo Nordisk for obesity and weight management. It works by mimicking the natural hormone amylin to slow digestion, signal fullness to the brain, and reduce appetite. It is primarily studied as a weekly injection, frequently combined with the GLP-1 receptor agonist semaglutide (known as CagriSema). [1, 2, 3, 4, 5, 6, 7]

How It Works

• Receptor targeting: Binds to amylin and calcitonin receptors in areas of the brain that control hunger and satiety.

• Gastric slowing: Delays stomach emptying to help prolong feelings of fullness after eating.

• Combination synergy: Paired with semaglutide in clinical trials to enhance overall weight loss compared to single-agent treatments.